Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow grows, but more slowly than its trailing trend
Q1 FY2026 free cash flow of $18.87M (cash outflow) rose 65.7% year over year, behind the +125.4% change in trailing-twelve-month free cash flow. Sequentially, it rose 30.8% from the prior quarter. Over 3 fiscal years it compounded at +72.7% a year.
Context
- Free cash flow grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +65.7% toward the trailing-twelve-month pace of +125.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (54.27M) USD
- Year-over-year change
- -198.2%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (54.27M) | -198.2% |
| FY2024 | 2024-12-31 | (18.2M) | -212.4% |
| FY2023 | 2023-12-31 | (5.82M) | +44.8% |
| FY2022 | 2022-12-31 | (10.54M) | — |
Free Cash Flow vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 free cash flow of $61.75M is the 6th largest of the 11 companies compared; the peer median is $62.16M.
- Its year-over-year change of +125.4% is the highest of 11, against a peer median of -10.5%.
- Over three fiscal years its annual growth of +72.7% compares with a peer median of +2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $101.64M | -28.6% | +4.9% | 907.3% | |
| LTM Mar 2026 | $87.42M | -8.8% | — | 309.7% | |
ZURAZura Bio Limited | LTM Mar 2026 | $72.75M | +112.3% | +70.1% | — |
| LTM Mar 2026 | $66.98M | +12.6% | -12.8% | 483.3% | |
| LTM Mar 2026 | $64.63M | -24.7% | -18.0% | 28725.3% | |
| LTM Mar 2026 | $61.75M | +125.4% | +72.7% | — | |
| LTM Mar 2026 | $59.69M | +14.1% | +24.2% | 101172.9% | |
| LTM Mar 2026 | $51.43M | -12.1% | +2.6% | — | |
| LTM Mar 2026 | $39.84M | -29.1% | -21.3% | 56.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $32.16M | +26.8% | +26.5% | — |
| LTM Mar 2026 | $9.61M | -88.3% | -28.2% | 13.9% | |
| Peer median (excluding AARD) | $62.16M | -10.5% | +2.6% | 483.3% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Depreciation & Amortization | 110K | 97K | 16K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 412K | 313K | 439K | 3.95M |
| Change in Working Capital | (1.31M) | (81K) | 1.57M | 356K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 31K | 776K | 798K | 239K |
| Other Working Capital | (1.34M) | (857K) | 775K | 117K |
| Other Non-Cash Items | 3.81M | 1.06M | 473K | 421K |
| Operating Cash Flow | (10.54M) | (5.82M) | (18.09M) | (54.17M) |
| Capital Expenditures | 0 | 0 | (109K) | (95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (11.89M) | (129.6M) |
| Sales of Investments | 0 | 0 | 0 | 80.03M |
| Other Investing Activities | (1M) | 0 | 0 | 0 |
| Investing Cash Flow | (1M) | 0 | (12M) | (49.67M) |
| Debt Repayment | (1M) | 0 | 0 | 0 |
| Common Stock Issued | 225K | 0 | 332K | 89.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1M | 0 | (3.34M) | 0 |
| Financing Cash Flow | 225K | 0 | 81.99M | 89.25M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.32M) | (5.82M) | 51.91M | (14.59M) |
| Free Cash Flow | (10.54M) | (5.82M) | (18.2M) | (54.27M) |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.